Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes
Overview
Authors
Affiliations
Objective: Overweight and obese individuals are encouraged to lose 5-10% of their body weight to improve cardiovascular disease (CVD) risk, but data supporting this recommendation are limited, particularly for individuals with type 2 diabetes.
Research Design And Methods: We conducted an observational analysis of participants in the Look AHEAD (Action For Health in Diabetes) study (n=5,145, 40.5% male, 37% from ethnic/racial minorities) and examined the association between the magnitude of weight loss and changes in CVD risk factors at 1 year and the odds of meeting predefined criteria for clinically significant improvements in risk factors in individuals with type 2 diabetes.
Results: The magnitude of weight loss at 1 year was strongly (P<0.0001) associated with improvements in glycemia, blood pressure, triglycerides, and HDL cholesterol but not with LDL cholesterol (P=0.79). Compared with weight-stable participants, those who lost 5 to <10% ([means±SD] 7.25±2.1 kg) of their body weight had increased odds of achieving a 0.5% point reduction in HbA1c (odds ratio 3.52 [95% CI 2.81-4.40]), a 5-mmHg decrease in diastolic blood pressure (1.48 [1.20-1.82]), a 5-mmHg decrease in systolic blood pressure (1.56 [1.27-1.91]), a 5 mg/dL increase in HDL cholesterol (1.69 [1.37-2.07]), and a 40 mg/dL decrease in triglycerides (2.20 [1.71-2.83]). The odds of clinically significant improvements in most risk factors were even greater in those who lost 10-15% of their body weight.
Conclusions: Modest weight losses of 5 to <10% were associated with significant improvements in CVD risk factors at 1 year, but larger weight losses had greater benefits.
Tronieri J, Ghanbari E, Chevinsky J, LaFata E, Minnick A, Rajpal S Nat Med. 2025; .
PMID: 40055520 DOI: 10.1038/s41591-025-03556-3.
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.
Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.
PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.
Bays H, Ard J, ONeil P, Wadden T, Kushner R, Jakicic J Obes Pillars. 2025; 13:100163.
PMID: 40028615 PMC: 11870181. DOI: 10.1016/j.obpill.2025.100163.
Odeniran O Cureus. 2025; 17(1):e78258.
PMID: 40026940 PMC: 11871983. DOI: 10.7759/cureus.78258.
Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement.
Xie D, Englund M, Lane N, Zhang Y, Li X, Wei J JAMA Netw Open. 2025; 8(2):e2461200.
PMID: 39982723 PMC: 11846009. DOI: 10.1001/jamanetworkopen.2024.61200.